Miller DB - Search Results

1

Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation.

Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Whitman SC, et al. Among authors: miller db. Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1707-15. doi: 10.1161/01.atv.17.9.1707. Arterioscler Thromb Vasc Biol. 1997. PMID: 9327767

2

Uptake of hypertriglyceridemic very low density lipoproteins and their remnants by HepG2 cells: the role of lipoprotein lipase, hepatic triglyceride lipase, and cell surface proteoglycans.

Huff MW, Miller DB, Wolfe BM, Connelly PW, Sawyez CG. Huff MW, et al. Among authors: miller db. J Lipid Res. 1997 Jul;38(7):1318-33. J Lipid Res. 1997. PMID: 9254059 Free article.

3

Oxidized type IV hypertriglyceridemic VLDL-remnants cause greater macrophage cholesteryl ester accumulation than oxidized LDL.

Whitman SC, Sawyez CG, Miller DB, Wolfe BM, Huff MW. Whitman SC, et al. Among authors: miller db. J Lipid Res. 1998 May;39(5):1008-20. J Lipid Res. 1998. PMID: 9610767 Free article.

4

The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.

Burnett JR, Barrett PH, Vicini P, Miller DB, Telford DE, Kleinstiver SJ, Huff MW. Burnett JR, et al. Among authors: miller db. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1906-14. doi: 10.1161/01.atv.18.12.1906. Arterioscler Thromb Vasc Biol. 1998. PMID: 9848883

5

Modification of type III VLDL, their remnants, and VLDL from ApoE-knockout mice by p-hydroxyphenylacetaldehyde, a product of myeloperoxidase activity, causes marked cholesteryl ester accumulation in macrophages.

Whitman SC, Hazen SL, Miller DB, Hegele RA, Heinecke JW, Huff MW. Whitman SC, et al. Among authors: miller db. Arterioscler Thromb Vasc Biol. 1999 May;19(5):1238-49. doi: 10.1161/01.atv.19.5.1238. Arterioscler Thromb Vasc Biol. 1999. PMID: 10323775

6

Uptake of type IV hypertriglyceridemic VLDL by cultured macrophages is enhanced by interferon-gamma.

Whitman SC, Argmann CA, Sawyez CG, Miller DB, Hegele RA, Huff MW. Whitman SC, et al. Among authors: miller db. J Lipid Res. 1999 Jun;40(6):1017-28. J Lipid Res. 1999. PMID: 10357833 Free article.

7

Identification, molecular characterization, and cellular studies of an apolipoprotein E mutant (E1) in three unrelated families with hyperlipidemia.

Miller DB, Hegele RA, Wolfe BM, Huff MW. Miller DB, et al. J Clin Endocrinol Metab. 1995 Mar;80(3):807-13. doi: 10.1210/jcem.80.3.7883834. J Clin Endocrinol Metab. 1995. PMID: 7883834

8

Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol.

Keyhan G, Rosset J, Wang J, Miller D, McManus R, Hegele RA. Keyhan G, et al. Clin Biochem. 2002 Jul;35(5):341-6. doi: 10.1016/s0009-9120(02)00322-3. Clin Biochem. 2002. PMID: 12270762

9

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

Miller DB, Spence JD. Miller DB, et al. Clin Pharmacokinet. 1998 Feb;34(2):155-62. doi: 10.2165/00003088-199834020-00003. Clin Pharmacokinet. 1998. PMID: 9515185 Review.

10

Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies.

Miller DB. Miller DB. Arch Intern Med. 1997 Oct 13;157(18):2045-52. Arch Intern Med. 1997. PMID: 9382659 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

335 results

Search Page

Filters